Ключевые аспекты ценообразования. Международная практика
Tools to Reduce Phase III Trial Failures Lawrence J. Lesko, Ph.D., FCP Director of the Office of Clinical Pharmacology and Biopharmaceutics Center for.
FDA Critical Path Initiative: A Generic Industry Perspective
Critical Path: Overview of Selected Ongoing CBER Efforts and Future Opportunities Jesse L. Goodman, M.D., M.P.H Director Center for Biologics Evaluation.
